Advances in the treatment of melanoma

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 12, Issue 2, 2012, Pages 168-171

  Lacy, Katie E ^a,b   Karagiannis, Sophia N ^a,b   Nestle, Frank O ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; CHLORMETHINE; CISPLATIN; DABRAFENIB; DACARBAZINE; DASATINIB; GLYCOPROTEIN GP 100; IMATINIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; NILOTINIB; ONCOLYTIC VIRUS; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; TALIMOGENE LAHERPAREPVEC; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB; VINCA ALKALOID;

ALOPECIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR DISEASE; COLITIS; COLORECTAL CANCER; DERMATITIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LUNG EDEMA; LUNG NON SMALL CELL CANCER; MELANOMA SKIN CANCER; NEUROTOXICITY; OVERALL SURVIVAL; PHOTOSENSITIVITY; PROGNOSIS; PRURITUS; RASH; SHORT SURVEY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84862569320     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.12-2-168     Document Type: Short Survey

References (15)

1. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
2. Nathan FE,Mastrangelo MJ. Systemic therapy in melanoma. Review. Semin Surg Oncol 1998;14:319-27. (Pubitemid 28211041)
3. Petrella T, Quirt I, Verma S et al Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Review. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484-96. (Pubitemid 47333669)
4. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-26. (Pubitemid 351952257)
5. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
6. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
7. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
8. Long GV, Kefford RF, Carr PJ et al. Phase Ù Study of GSK2118436, a Selective Inhibitor of V600 Mutant (Mut)BRAF Kinase: Evidence of Activity in Melanoma Brain Metastases (Mets). Ann Oncol 2010;21:Abstract 12.
9. Infante J, Falchook G, Lawrence D et al. Phase I/II study to assess safety, pharmacokinetics and efficacy of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK 436). J Clin Oncol 2011;29:CRA8503.
10. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6. (Pubitemid 46630793)
11. Carvajal RD, Antonescu CR,Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.
12. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H.Melanoma: New Insights and New Therapies. J Invest Dermatol 2012 Jan 5.doi:10.1038/jid.2011.421 [Epub ahead of print].
13. Del Vecchio M,Mortarini R, Canova S et al. Bevacizumab plus fotemustine as firstline treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16:5862-72.
14. Brahmer JR, Drake CG,Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
15. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocytemacrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71.